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Introduction
============

In the UK, pancreatic ductal adenocarcinoma (PDAC) is the 10 ^th^ commonest cancer and has an incidence of 9 per 100,000 population ^[@ref-1]^, and biliary tract cancer (BTC) (including intra- and extra-hepatic cholangiocarcinoma and gallbladder cancer) has an incidence of 1--2 cases per 100,000 population ^[@ref-2]^. Long-term survival is poor; 5-year survival is less than 4% for both tumours ^[@ref-3],\ [@ref-4]^. Often these tumours are diagnosed late, when patients have advanced disease and curative surgical resection is no longer possible.

Globally the highest incidence of PDAC is seen in Northern Europe and North America ^[@ref-5]^, where the rates are 3 to 4 times higher than in tropical countries ^[@ref-6]^. Overall incidence is increasing ^[@ref-5]^, and as most tumours are sporadic, this rising incidence is attributed to differences in lifestyles and exposure to environmental risk factors ^[@ref-7]^, such as smoking ^[@ref-8]--\ [@ref-15]^, diabetes mellitus, chronic pancreatitis ^[@ref-1],\ [@ref-15],\ [@ref-16]^ and obesity ^[@ref-17]^.

In BTC, the variations in incidence seen globally are even more pronounced; and the highest incidence is in northeastern Thailand (96 per 100,000 men) ^[@ref-18]^, which has a population with high levels of chronic typhoid and infestation of liver fluke ( *Clonorchis sinensis* and *Opisthorchis viverinni*) ^[@ref-18]^. Other BTC risk factors seen in all populations include older age ^[@ref-18]^, primary sclerosing cholangitis ^[@ref-19]^, intraductal stones and rare biliary cystic diseases ^[@ref-20]^. Inflammatory bowel disease, chronic viral hepatitis, cirrhosis, smoking, diabetes, obesity and excess alcohol consumption may also increase the risk of BTC ^[@ref-20]--\ [@ref-22]^.

Despite improved diagnostic techniques, detecting pancreaticobiliary malignancy remains a significant clinical challenge. A common presentation of these tumours is a biliary stricture with or without a mass lesion. The differential of an indeterminate biliary stricture is broad, and often the associated symptoms and radiological findings overlap between benign and malignant conditions, often making differentiation---particularly between cancer, primary sclerosing cholangitis and IgG4-related disease---impossible without further investigations, typically by endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS) ^[@ref-23]--\ [@ref-25]^. However, biliary brush cytology is also an imperfect test, although specificity is high (96--100%), sensitivity for malignancy remains low (9--57%) and in early disease when tumours are small, sensitivities are even lower ^[@ref-26],\ [@ref-27]^. Therefore, patients frequently require multiple procedures to obtain a final diagnosis ^[@ref-28]--\ [@ref-30]^.

So there has been growing interest in the development of simple tests to streamline the diagnosis to pancreaticobiliary malignancy and guide appropriate and timely therapy for patients. Identifying better diagnostic tools for PDAC and BTC would also make screening and surveillance possible, particularly in high-risk populations ^[@ref-4],\ [@ref-8],\ [@ref-31]^. This would enable the detection of tumours at an earlier stage when curative resection is possible, leading to substantial improvements in survival ^[@ref-32]^. This review provides an overview of the latest innovations in diagnostic biomarkers and endoscopic techniques for pancreaticobiliary malignancy.

Methods
=======

We performed a systematic review of the literature by using PubMed, EMBASE and the Cochrane Library. The search was limited to studies published in the English language between January 2013 and March 2017. Medical Subject Headings (MeSH) terms were decided by a consensus of the authors and included "pancreatic cancer" or "cholangiocarcinoma" and "biomarker". The search was restricted to title, abstract and keywords. Articles that described outcomes for fewer than five patients were excluded. Case reports, abstracts and reviews were excluded. All references were screened for potentially relevant studies not identified in the initial literature search.

The following variables were extracted for each report when available: number of malignant and benign cases, sensitivity, specificity and area under the curve (AUC). One hundred ten articles were included in the final review.

Biomarkers
==========

1. Serum biomarkers and blood tests
-----------------------------------

Carbohydrate antigen (CA) 19-9 is the most widely used tumour marker in pancreaticobiliary malignancy. Overall sensitivity (78--89%) and specificity (67--87%) are low, and in around 7% of the population who lack the Lewis (a) antigen, CA19-9 will remain negative ^[@ref-33]^. In small tumours, sensitivity decreases further. The marker can also be elevated in a number of other malignant diseases (for example, gastric adenocarcinoma) and benign diseases, particularly those causing jaundice (for example, primary biliary cirrhosis, cholestasis and cholangitis), and in smokers ^[@ref-34]^. In addition, variation has been reported among commercially available assays, which may impact on interpretation ^[@ref-35]^. Therefore, to improve the sensitivity of the marker in current clinical practice, it is always interpreted in the context of cross-sectional imaging findings ^[@ref-33]^.

Other commercially available tumour markers that have a role in diagnosing pancreaticobiliary cancer include carcinoembryonic antigen (CEA) and CA125. CEA is a glycosyl phosphatidyl inositol cell surface-anchored glycoprotein that is involved in cell adhesion. When elevated, it is highly suggestive of colorectal cancer, but it is also increased in about a third of patients with BTC ^[@ref-36]--\ [@ref-38]^. CA125 is a protein encoded by the *MUC16* gene and is a large membrane-associated glycoprotein with a single transmembrane domain. When elevated, it is suggestive of ovarian cancer, but it is also increased in about 40--50% of patients with pancreaticobiliary malignancy, particularly when there is peritoneal involvement ^[@ref-38]^.

Owing to the limitations of existing biomarkers, over the last few years several studies have evaluated various combinations of biomarkers to supplement or ultimately replace existing biomarkers. Biomarker panels using combinations of markers, often including CA19-9, have been particularly successful in detecting small tumours and early disease. Validation studies have also shown that these markers can differentiate PDAC from relevant benign conditions and in some cases detect tumours up to 1 year prior to diagnosis with a specificity of 95% and a sensitivity of 68% ^[@ref-7]^ ( [Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"}).

###### Serum protein biomarkers for biliary tract cancer, 2013--2017.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                             Biomarker/\         Biliary tract\      Benign lesion/\   Healthy\       Sensitivity   Specificity   Area\
                                            Combination\        cancer, number      cholangitis,\     volunteers,\                               under the\
                                            (serum)                                 number            number                                     curve
  ----------------------------------------- ------------------- ------------------- ----------------- -------------- ------------- ------------- ------------
  Single biomarkers                                                                                                                              

  Han *et al*. (2013) ^[@ref-84]^           HDGF                83                  \-                51             66%           88%           0.81

  Ruzzenente *et al*. (2014) ^[@ref-85]^    MUC5AC              49                  23                16             \-            \-            0.91

  Voigtlander *et al*. (2014) ^[@ref-86]^   Angpt-2             56                  111               \-             74%           94%           0.85

  Lumachi *et al*. (2014) ^[@ref-87]^       CA 19-9             24                  25                \-             74%           82%           \-

  Wang *et al*. (2014) ^[@ref-88]^          CA 19-9             78                  78                78             72%           96%           \-

  Lumachi *et al*. (2014) ^[@ref-87]^       CEA                 24                  25                \-             52%           55%           \-

  Wang *et al*. (2014) ^[@ref-88]^          CEA                 78                  78                78             11%           97%           \-

  Wang *et al*. (2014) ^[@ref-88]^          CA 125              78                  78                78             45%           96%           \-

  Lumachi *et al*. (2014) ^[@ref-87]^       CYFRA 21-1          24                  25                \-             76%           79%           \-

  Liu *et al*. (2015) ^[@ref-89]^           VEGF-C              31                  10                10             71%           80%           0.79

  Liu *et al*. (2015) ^[@ref-89]^           VEGF-D              31                  10                10             74%           85%           0.84

  Huang *et al*. (2015) ^[@ref-90]^         CYFRA 21-1          134                 52                \-             75%           85%           \-

  Lumachi *et al*. (2014) ^[@ref-87]^       MMP7                24                  25                \-             78%           77%           \-

  Nigam *et al*. (2014) ^[@ref-91]^         Survivin            39 (gallbladder\    30                25             81%           80%           \-
                                                                cancer)                                                                          

  Rucksaken *et al*. (2014) ^[@ref-92]^     HSP70               31\                 12                23             94%\          74%\          0.92\

  Rucksaken *et al*. (2014) ^[@ref-92]^     ENO1                31                  \-                23             81%           78%           0.86

  Rucksaken *et al*. (2014) ^[@ref-92]^     RNH1                31                  \-                23             94%           67%           0.84

  Wang *et al*. (2014) ^[@ref-88]^          CA242               78                  78                78             64%           99%           \-

  Ince *et al*. (2014) ^[@ref-93]^          VEGFR3              96                  129               \-             48%           82%           0.62

  Ince *et al*. (2014) ^[@ref-93]^          TAC                 96                  129               \-             61%           60%           0.60

  Rucksaken *et al*. (2017) ^[@ref-94]^     ORM2                70                  46                20             92%           74%           \-

  Rose *et al*. (2016) ^[@ref-95]^          CEACAM6             41                  42                \-             87.5%         69%           0.74

  Jiao *et al*. (2014) ^[@ref-96]^          Nucleosides         202 (gallbladder\   203               205            91%           96%           \-
                                                                cancer)                                                                          

  Biomarker combinations                                                                                                                         

  Lumachi *et al*. (2014) ^[@ref-87]^       CEA + CA19-9 +\     24                  25                \-             92%           96%           
                                            CYFRA 21-1 + MMP7                                                                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

###### Serum protein biomarkers for pancreatic cancer, 2012--2017.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                              Biomarker/\          PDAC, number            Benign\         Healthy\       Sensitivity   Specificity   Area\
                                             Combination\                                 controls,\      volunteers,\                               under\
                                             (serum)                                      number          number                                     the\
                                                                                                                                                     curve
  ------------------------------------------ -------------------- ----------------------- --------------- -------------- ------------- ------------- --------
  Single biomarkers                                                                                                                                  

  Sogawa *et al*. (2016) ^[@ref-97]^         C4BPA                52                      20              40             67%           95%           0.860

  Rychlikova *et al*. (2016) ^[@ref-98]^     Osteopontin          64                      71              48             \-            \-            \-

  Lin *et al*. (2016) ^[@ref-99]^            APOA-I               78                      \-              36             96%           72.2%         0.880

  Lin *et al*. (2016) ^[@ref-99]^            TF                   78                      \-              36             75%           72.8%         0.760

  Guo *et al*. (2016) ^[@ref-100]^           Dysbindin            250                     80              150            81.9%         84.7%         0.849

  Han *et al*. (2015) ^[@ref-101]^           Dickkopf-1           140                     \-              92             89.3%         79.3%         0.919

  Qu *et al*. (2015) ^[@ref-102]^            DCLK1                74                      74              \-             \-            \-            0.740

  Dong *et al*. (2015) ^[@ref-103]^          Survivin             80                      \-              80             \-            \-            \-

  Gebauer *et al*. (2014) ^[@ref-104]^       EpCAM                66                      43              104            66.7%         77.5%         \-

  Wang *et al*. (2014) ^[@ref-105]^          MIC-1                807                     165             500            65.8%         96.4%         0.935

  Kendrick *et al*. (2014) ^[@ref-106]^      IGFBP2               84                      40              84             22%           95%           0.655

  Kendrick *et al*. (2014) ^[@ref-106]^      MSLN                 84                      40              84             17%           95%           0.668

  Kang *et al*. (2014) ^[@ref-107]^          COL6A3               44                      46              30             \-            \-            0.975

  Willumsen *et al*. (2013) ^[@ref-108]^     C1M                  15                      \-              33             \-            \-            0.830

  Willumsen *et al*. (2013) ^[@ref-108]^     C3M                  15                      \-              33             \-            \-            0.880

  Willumsen *et al*. (2013) ^[@ref-108]^     C4M                  15                      \-              33             \-            \-            0.940

  Willumsen *et al*. (2013) ^[@ref-108]^     C4M12a1              15                      \-              33             \-            \-            0.890

  Falco *et al*. (2013) ^[@ref-109]^         BAG3                 52                      \-              44             75%           75%           0.770

  Falco *et al*. (2013) ^[@ref-109]^         BAG3                 52                      17 (chronic\    \-             81%           77%           0.810
                                                                                          pancreatitis)                                              

  Chen *et al*. (2013) ^[@ref-110]^          TTR                  40                      \-              40             91%           47%           0.730

  Gold *et al*. (2013) ^[@ref-111]^          PAM4                 298                     \-              79             76%           96%           \-

  Gold *et al*. (2013) ^[@ref-111]^          PAM4                 298                     120             \-             \-            \-            0.890

  Poruk *et al*. (2013) ^[@ref-112]^         OPN                  86                      48              86             \-            \-            0.720

  Poruk *et al*. (2013) ^[@ref-112]^         TIMP-1               86                      48              86             \-            \-            0.770

  Lee *et al.* (2014) ^[@ref-113]^           CA 19-9              41                      12              44             80.4%         70%           0.833

  Lee *et al.* (2014) ^[@ref-113]^           Human\               41                      12              44             73.1%         97.9%         0.958
                                             complement\                                                                                             
                                             factor B (CFB)                                                                                          

  Mixed cohorts                                                                                                                                      

  Ince *et al*. (2014) ^[@ref-93]^           CEA                  96 (41 PDAC +25 BTC)    129             \-             42.7%         89.9%         0.713

  Ince *et al*. (2014) ^[@ref-93]^           CA19-9               96 (41 PDAC +25 BTC)    129             \-             49%           84.5%         0.701

  Ince *et al*. (2014) ^[@ref-93]^           VEGFR3               96 (41 PDAC +25 BTC)    129             \-             48.4%         82.9%         0.622

  Ince *et al*. (2014) ^[@ref-93]^           Total antioxidant\   96 (41 PDAC +25 BTC)    129             \-             61.1%         60.5%         0.602
                                             capacity                                                                                                

  Abdel-Razik *et al*. (2016) ^[@ref-114]^   IGF-1                47 (25 PDAC + 18 BTC)   62              \-             62%           51%           0.605

  Abdel-Razik *et al*. (2016) ^[@ref-114]^   VEGF                 47 (25 PDAC + 18 BTC)   62              \-             58.3%         57.3%         0.544

  Biomarker combinations                                                                                                                             

  Chen *et al*. (2013) ^[@ref-110]^          TTR + CA19-9         40                      \-              40             81%           85%           0.910

  Lee *et al*. (2014) ^[@ref-113]^           CA19-9 + CFB         41                      12              44             90.1%         97.2%         0.986

  Sogawa *et al*. (2016) ^[@ref-97]^         C4BPA + CA19-9       52                      20              40             86%           80%           0.930

  Makawita *et al*. (2013) ^[@ref-115]^      CA19-9 + REG1B       100                     \-              92             \-            \-            0.880

  Makawita *et al*. (2013) ^[@ref-115]^      CA19-9 + SYCN\       100                     \-              92             \-            \-            0.870
                                             + REG1B                                                                                                 

  Willumsen *et al*. (2013) ^[@ref-108]^     C1M + C3M +\         15                      \-              33             \-            \-            0.990
                                             C4M + C4M12a1                                                                                           

  Shaw *et al*. (2014) ^[@ref-116]^          IL10 + IL6 +\        84                      45 (benign)     \-             93%           58%           0.840\
                                             PDGF + Ca19-9                                                                                           

  Shaw *et al*. (2014) ^[@ref-116]^          IL8 + IL6 +\         84                      32 (chronic\    \-             75%           91%           0.880\
                                             IL-10 + Ca19-9                               pancreatitis)                                              

  Shaw *et al*. (2014) ^[@ref-116]^          IL8 + IL1b +\        127                     \-              45             94%           100%          0.857
                                             Ca 19-9                                                                                                 

  Brand *et al*. (2011) ^[@ref-117]^         Ca-19 + CEA +\       173                     70              120            71%           89%           \-
                                             TIMP-1                                                                                                  

  Capello *et al*. (2017) ^[@ref-118]^       TIMP1 + LRG1\        73                      \-              60             0.849%        0.633%        0.949
                                             + Ca19-9                                                                                                

  Capello *et al*. (2017) ^[@ref-118]^       TIMP1 + LRG1\        73                      74              \-             0.452%        0.541%        0.890
                                             + Ca19-9                                                                                                

  Chan *et al*. (2014) ^[@ref-119]^          Ca19-9 + Ca125\      139                     65              10             82%           74%%          0.870
                                             + LAMC2                                                                                                 

  Makawita *et al*. (2013) ^[@ref-115]^      CA19-9 + REG1B       82                      41              92             \-            \-            0.875

  Makawita *et al*. (2013) ^[@ref-115]^      CA19-9 + SYNC\       82                      41              92             \-            \-            0.873
                                             + REG1B                                                                                                 

  Makawita *et al*. (2013) ^[@ref-115]^      CA19-9 + AGR2\       82                      41              92             \-            \-            0.869
                                             + REG1B                                                                                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

BTC, biliary tract cancer; PDAC, pancreatic ductal adenocarcinoma.

In pancreaticobiliary malignancy and PDAC in particular, metastatic disease occurs at a very early stage in tumour development. This is demonstrated by the fact that patients who underwent resection of small primary tumours (\<2 cm) with no clinical evidence of metastatic disease had a 5-year survival after pancreatectomy of less than 18% owing to recurrent metastatic disease ^[@ref-39]^. Tumour development is driven by a series of cumulative genetic abnormalities; therefore, genetic and epigenetic changes have been explored as diagnostic targets in circulating tumour cells, cell-free DNA (cfDNA) and non-coding RNA ( [Table 3](#T3){ref-type="table"}-- [Table 5](#T5){ref-type="table"}). Owing to the position and composition of pancreaticobiliary tumours, tissue samples are frequently acellular, making diagnostics challenging. Recently, the utility of next-generation sequencing was explored as a technique that allows the detection of low-abundance mutations and abnormalities in small amounts of material ^[@ref-40]^. Changes in the metabalome are also being explored as a potential diagnostic tool in pancreaticobiliary malignancy ^[@ref-41]^.

###### Genetic and epigenetic alterations in circulating tumour cells in pancreatic ductal adenocarcinoma and biliary tract cancer, 2013--2017.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                                 Target                    Biliary\   Pancreatic ductal\    Benign\     Healthy\       Detected                       Sensitivity   Specificity   Area\
                                                                          tract\     adenocarcinoma,\      lesions,\   volunteers,\                                                              under\
                                                                          cancer,\   number                number      number                                                                    the\
                                                                          number                                                                                                                 curve
  --------------------------------------------- ------------------------- ---------- --------------------- ----------- -------------- ------------------------------ ------------- ------------- --------
  Ankeny *et al*. (2016) ^[@ref-120]^           K-ras                     \-         72                    28          \-             \-                             75%           96.4%         0.867

  Kulemann *et al*. (2016) ^[@ref-121]^         K-ras                     \-         21                    \-          10             80% (stage IIA/IIB)\           \-            \-            \-
                                                                                                                                      91% (stage III/IV)                                         

  Singh *et al*. (2015) ^[@ref-122]^            ctDNA,\                   \-         \-                    \-          \-             \-                             65.3%         61.5%         0.6681
                                                K-ras                                                                                                                                            

  Kinugasa *et al*. (2015) ^[@ref-123]^         K-ras                     \-         141                   20          20             \-                             62.6%         \-            \-

  Takai *et al*. (2015) ^[@ref-124]^            K-ras                     \-         259                   \-          \-             \-                             29.2%         \-            \-

  Sausen *et al*. (2015) ^[@ref-125]^           ctDNA                     \-         77                    \-          \-             \-                             43%           \-            \-

  Kulemann *et al*. (2015) ^[@ref-126]^         CTC\                      \-         11                    \-          9              75% (stage IIb)\               \-            \-            \-
                                                K-ras                                                                                 71% (stage III)                                            

  Zhang *et al*. (2015) ^[@ref-127]^            DAPI ^+^, CD45-,\         \-         22\                   6\          30\            68.2%                          \             \             \
                                                CK ^+^,\                             Validation cohort:\   \           \                                             \             \             \
                                                CEP8 \> 2 ^+^                        11                    8           10                                            \             \             \
                                                                                                                                                                     63.6%         94.4%         0.84

  Wu *et al*. (2014) ^[@ref-128]^               K-ras                     \-         36                    \-          25             \-                             0             0             \-

  Bidard *et al*. (2013) ^[@ref-129]^           CK,\                      \-         79                    \-          \-             11%                            \-            \-            \-
                                                CD45                                                                                                                                             

  Bobek *et al*. (2014) ^[@ref-130]^            DAPI,\                    \-         24                    \-          \-             66.7%                          \-            \-            \-
                                                CK,\                                                                                                                                             
                                                CEA, Vimentin                                                                                                                                    

  Rhim *et al*. (2014) ^[@ref-131]^             DAPI, CD45,\              \-         11                    21          19             78%                            \-            \-            \-
                                                CK,\                                                                                                                                             
                                                PDX-1                                                                                                                                            

  Iwanicki-Caron *et al*. (2013) ^[@ref-132]^   CTC                       \-         40                    \-          \-             \-                             55.5%         100%          \-

  Sheng *et al*. (2014) ^[@ref-133]^            CTC                       \-         18                    \-          \-             94.4%                          \-            \-            \-

  Catebacci *et al*. (2015) ^[@ref-134]^        CTC (in portal venous\    2          14                    \-          \-             100% (pulmonary vein blood)\   \-            \-            \-
                                                blood at EUS)                                                                         22.2% (peripheral blood)                                   

  Earl *et al*. (2015) ^[@ref-135]^             CTC                       \-         35                    \-          \-             20%                            \-            \-            \-

  Cauley *et al*. (2015) ^[@ref-136]^           Circulating epithelial\   \-         105                   34          9              49%                            \-            \-            \-
                                                cells                                                                                                                                            

  Kamande *et al*. (2013) ^[@ref-137]^          DAPI, CD45,\              \-         12                    \-          \-             100%                           \-            \-            \-
                                                CK                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Genetic and epigenetic alterations in circulating cell-free DNA pancreatic ductal adenocarcinoma and biliary tract cancer, 2013--2017.

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                           Target          PDAC\    Cancer,\     Benign\     Healthy\       Detected   Sensitivity   Specificity
                                                          or BTC   number       lesions,\   volunteers,\                            
                                                                                number      number                                  
  --------------------------------------- --------------- -------- ------------ ----------- -------------- ---------- ------------- -------------
  Takai *et al*. (2016) ^[@ref-138]^      K-ras           PDAC     107 (non-\   \-          \-             59%        \-            \-
                                                                   operable)                                                        

  Takai *et al*. (2015) ^[@ref-124]^      cfDNA           PDAC     48                                      29%                       

  Hadano *et al*. (2016) ^[@ref-139]^     K-ras           PDAC     105          \-          20             31%        \-            \-

  Zill *et al*. (2015) ^[@ref-140]^       K-ras, TP53,\   PDAC     26           \-          \-             \-         92.3%         100%
                                          APC, FBXW7,\                                                                              
                                          SMAD4                                                                                     

  Earl *et al*. (2015) ^[@ref-135]^       K-ras           PDAC     31           \-          \-             26%        \-            \-

  Kinusaga *et al*. (2015) ^[@ref-123]^   G12V, G12D,\    PDAC     141          20          20             62%        \-            \-
                                          and G12R in\                                                                              
                                          codon 12 of\                                                                              
                                          K-ras gene                                                                                

  Sausen *et al*. (2015) ^[@ref-125]^     cfDNA           PDAC     77           \-          \-             43%        \-            \-

  Wu *et al*. (2014) ^[@ref-128]^         K-ras           PDAC     24           \-          25             72%        \-            \-
  -----------------------------------------------------------------------------------------------------------------------------------------------

BTC, biliary tract cancer; PDAC, pancreatic ductal adenocarcinoma.

###### Epigenetics: circulating non-coding RNA and DNA methylation markers in pancreatic ductal adenocarcinoma/biliary tract cancer, 2013--2017.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                               MicroRNA                 Biliary\   Pancreatic\        Benign\     Healthy\       Sensitivity   Specificity   Area\
                                                                       tract\     ductal\            lesions,\   volunteers,\                               under\
                                                                       cancer,\   adenocarcinoma,\   number      number                                     the\
                                                                       number     number                                                                    curve
  ------------------------------------------- ------------------------ ---------- ------------------ ----------- -------------- ------------- ------------- --------
  Circulating non-coding RNA                                                                                                                                

  Kishimoto *et al*. (2013) ^[@ref-141]^      MiR-21 (↑)               94\        \-\                \-\         50\            85%\          100%\         0.93\
                                                                       94         -                  23          -              72.3%         91.3%         0.83

  Wang *et al*. (2013) ^[@ref-142]^           miR-27a-3p + CA19-9(↑)   \-         129                103         60             85.3%         81.6%         0.886

  Kawaguchi *et al*. (2013) ^[@ref-143]^      miR-221 (↑),\            \-         47                 \-          30             \-            \-            0.762
                                              miR-375 (↓)                                                                                                   

  Zhao *et al*. (2013) ^[@ref-144]^           miR-192 (↑)              \-         70                 \-          40             76%           55%           0.63

  Carleson *et al*. (2013) ^[@ref-145]^       MiR-375 (↑)              \-         48                 47          \-             \-            \-            0.72

  Que *et al*. (2013) ^[@ref-146]^            miR-17-5p (↑)\           \-         22                 12          8              \-            \-            0.887\
                                              miR-21 (↑),                                                                                                   0.897

  Schultz *et al*. (2014) ^[@ref-147]^        Index I + CA19-9\        \-         409                25          312            85%\          88%\          0.93\
                                              Index II + CA19-9                                                                 85%           86%           0.92

  Silakit *et al*. (2014) ^[@ref-148]^        MiR-192 (↑)              11         \-                 \-          9              74%           72%           0.803

  Lin *et al*. (2015) ^[@ref-149]^            MiR-492 (↑)\             \-         49                 \-          27             75%\          70%\          0.787\
                                              MiR-663a (↑)                                                                      85%           80%           0.870

  Chen *et al*. (2014) ^[@ref-150]^           miR-182 (↑)              \-         109                38          50             64.1%         82.6%         0.775

  Wang *et al*. (2015) ^[@ref-151]^           MiR-150 (↑)              15         \-                 \-          15             80%           58%           0.764

  Ganepola *et al*. (2015) ^[@ref-152]^       miR-22 (↑),\             \-         11                 \-          11             91%           91%           0.970
                                              miR-642b (↑)\                                                                                                 
                                              miR-885-5p (↑)                                                                                                

  Voigtlander *et al*. (2015) ^[@ref-153]^\   MiR-1281 (↑)\            31         \-                 40          \-             55%\          90%\          0.83\
  (serum)                                     MiR-126 (↑)\                                                                      68%\          93%\          0.87\
                                              MiR-26a (↑)\                                                                      52%\          93%\          0.78\
                                              MiR-30b (↑)\                                                                      52%\          88%\          0.78\
                                              MiR-122 (↑)                                                                       32%           90%           0.65

  Voigtlander *et al*. (2015) ^[@ref-153]^\   miR-412 (↑)\             31         \-                 53          \-             50%\          89%\          0.81\
  (bile)                                      miR-640 (↑)\                                                                      50%\          92%\          0.81\
                                              miR-1537 (↑)\                                                                     67%\          90%\          0.78\
                                              miR-3189 (↑)                                                                      67%           89%           0.80

  Abue *et al*. (2015) ^[@ref-154]^           miR-21 (↑),\             \-         32                 12          30             \-            \-            0.790\
                                              miR-483-3p (↑)                                                                                                0.754

  Salter *et al*. (2015) ^[@ref-155]^         miR-196a (↑),\           \-         19                 10          10             100%          90%           0.99
                                              miR-196b (↑)                                                                                                  

  Kojima *et al*. (2015) ^[@ref-156]^         miR-6075,\               98         100                21          150            80.3%         97.6%         0.953
                                              miR-4294,\                                                                                                    
                                              miR-6880-5p,\                                                                                                 
                                              miR-6799-5p,\                                                                                                 
                                              miR-125a-3p,\                                                                                                 
                                              miR-4530,\                                                                                                    
                                              miR-6836-3p,\                                                                                                 
                                              miR-4476                                                                                                      

  Xu *et al*. (2015) ^[@ref-157]^             miR-486-5p (↑)\          \-         156                142         65             \-            \-            0.861\
                                              miR-938 (↑)                                                                                                   0.693

  Madhaven *et al*. (2015) ^[@ref-158]^       PaCIC + miRNA\           \-         \-                 \-          \-             100%          80%           \-
                                              serum-exosome\                                                                                                
                                              marker panel                                                                                                  

  Komatsu *et al*. (2015) ^[@ref-159]^        miR-223 (↑)              \-         71                 \-          67             62%           94.1%         0.834

  Alemar *et al*. (2016) ^[@ref-160]^         MiR-21 (↑)\              \-         24                 \-          10             \-            \-            0.889\
                                              MiR-34a (↑)                                                                                                   0.865

  Wu *et al*. (2016) ^[@ref-161]^             MiR-150 (↓)              30         30                 28          50             \-            \-            \-

  Bernuzzi *et al*. (2016) ^[@ref-162]^       MiR-483-5p(↑)\           40         40                 70          40             \-            \-            0.77\
                                              MiR-194(↑)                                                                                                    0.74

  Kim *et al*. (2016) ^[@ref-163]^            mRNA -- CDH3 (↑)\        \-         21                 14          \-             57.1%\        64.3%\        0.776\
                                              mRNA --IGF2BP3(↑)\                                                                76.2%\        100%\         0.476\
                                              mRNA -- HOXB7 (↑)\                                                                71.4%\        57.1%\        0.898\
                                              mRNA -- BIRC5 (↑)                                                                 76.2%         64.3%         0.818

  Duell *et al*. (2017) ^[@ref-164]^          MiR-10a (↑)\             \-         225                \-          225            \-            \-            0.66\
                                              MiR-10b (↑)\                                                                                                  0.68\
                                              MiR-21-5p (↑)\                                                                                                0.64\
                                              MiR-30c (↑)\                                                                                                  0.71\
                                              MiR-155 (↑)\                                                                                                  0.64\
                                              MiR-212 (↑)                                                                                                   0.64

  DNA hypermethylation                                                                                                                                      

  Branchi *et al*. (2016) ^[@ref-165]^        *SHOX2*/ *SEPT9*         20         \-                 \-          100            0.45%         0.99%         0.752
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

2. Bile and biliary brush biomarkers
------------------------------------

Patients with an indeterminate stricture on cross-sectional imaging are typically referred for an ERCP and biliary brushing with or without endobilary biopsy to obtain tissue for diagnosis, with or without therapeutic stenting ^[@ref-28]^. Although these techniques do not compromise resection margins in potentially resectable cases, sensitivity remains low (9--57%) and patients frequently have to undergo multiple procedures to obtain a diagnosis ^[@ref-28]--\ [@ref-30]^. Bile can be easily obtained at the time of ERCP and, owing to its proximity to the tumour, is a potentially important source of diagnostic biomarkers in these cancers ( [Table 6](#T6){ref-type="table"}). Unfortunately, owing to the invasiveness of ERCP, the role of these biomarkers is limited to diagnosis rather than screening or surveillance in these tumours.

###### Bile and biliary brush biomarkers for pancreatic and biliary tract cancer.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                       Biomarker            Pancreatic ductal\   Biliary tract\   Benign\     Healthy\     Bile or\   Sensitivity   Specificity   Area\
                                                           adenocarcinoma,\     cancer,\         lesions,\   controls,\   biliary\                               under\
                                                           number               number           number      number       brush                                  the\
                                                                                                                                                                 curve
  ----------------------------------- -------------------- -------------------- ---------------- ----------- ------------ ---------- ------------- ------------- --------
  Single biomarkers                                                                                                                                              

  Dhar *et al*. (2013) ^[@ref-166]^   M2-PK                \-                   88               79          17           Bile       90.3%         84.3%         \-

  Navaneethan\                        M2-PK                \-                   \-               \-          \-           Bile       52.9%         94.1%         0.77
  *et al*. (2015) ^[@ref-167]^                                                                                                                                   

  Keane (2017) ^[@ref-168]^           MCM5                 24                   17               47                       Biliary\   55.6%         77.8%         0.79
                                                                                                                          brush                                  

  Danese *et al*.\                    MUC5AC               \-                   20               20          \-           Serum\     \-            \-            0.94\
  (2014) ^[@ref-169]^                                                                                                     Bile                                   0.99

  Farina *et al*.\                    CEAM6                23                   6                12          \-           Bile       93%           83%           0.92
  (2014) ^[@ref-170]^                                                                                                                                            

  Budzynska *et al*.\                 NGAL                 6                    16               18          \-           Bile       77%           72%           0.74
  (2013) ^[@ref-171]^                                                                                                                                            

  Jiao *et al*. (2014) ^[@ref-96]^    Nucleosides                               202\             203         205          Bile       95.3%         96.4%         \-
                                                                                (gallbladder\                                                                    
                                                                                cancer)                                                                          

  Ince *et al*. (2014) ^[@ref-93]^    CE                   41                   25               129         \-           Bile       57.3%         68.2%         0.516

  Ince *et al*. (2014) ^[@ref-93]^    CA 19-9              41                   25               129         \-           Bile       74.0%         34.1%         0.616

  Ince *et al*. (2014) ^[@ref-93]^    VEGFR3               41                   25               129         \-           Bile       56.2%         79.1%         0.663

  Ince *et al*. (2014) ^[@ref-93]^    Total antioxidant\   41                   25               129         \-           Bile       65.6%         50.4%         0.581
                                      capacity                                                                                                                   

  Abdel-Razik *et al*.\               IGF-1                25                   18               62          \-           Bile       91.4%         89.5%         0.943
  (2016) ^[@ref-114]^                                                                                                                                            

  Abdel-Razik *et al*.\               VEGF                 25                   18               62          \-           Bile       90.3%         84.9%         0.915
  (2016) ^[@ref-114]^                                                                                                                                            

  Kim *et al*. (2016) ^[@ref-163]^    mRNA -- CDH3 (↑)\    \-                   21               14          \-           Biliary\   57.1%\        64.3%\        0.776\
                                      mRNA --IGF2BP3(↑)\                                                                  brush      76.2%\        100%\         0.476\
                                      mRNA -- HOXB7 (↑)\                                                                             71.4%\        57.1%\        0.898\
                                      mRNA -- BIRC5 (↑)                                                                              76.2%         64.3%         0.818
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

3. Urinary biomarkers
---------------------

Urine provides a very easy and acceptable source for biomarker analysis. In BTC, a 42-peptide panel (consisting mostly of fragments of interstitial collagens) correctly identified 35 of 42 BTC patients with a sensitivity of 83% and a specificity of 79% ^[@ref-42]^. In PDAC, the three-biomarker panel (LYVE-1, REG1A and TFF1) has been validated in a multi-centre cohort of 371 samples. When comparing PDAC stage I--IIA (resectable disease) with healthy urines, the panel achieved AUCs of 0.97 (95% confidence interval of 0.93--1.00). The performance of the urine biomarker panel in discriminating PDAC stage I--IIA was superior to the performance of serum CA19-9 ( *P*=0.006) ^[@ref-43]^ ( [Table 7](#T7){ref-type="table"}).

###### Summary of urine protein biomarkers for pancreatic and biliary tract cancer, 2013--2017.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                         Biomarker/\        Pancreatic ductal\   Biliary tract\   Benign\          Healthy\       Sensitivity   Specificity   Area\
                                        Combination\       adenocarcinoma,\     cancer,\         cancer/\         volunteers,\                               under\
                                        (urine)            number               number           Chronic\         number                                     the\
                                                                                                 pancreatitis,\                                              curve
                                                                                                 number                                                      
  ------------------------------------- ------------------ -------------------- ---------------- ---------------- -------------- ------------- ------------- --------
  Single biomarker                                                                                                                                           

  Roy *et al*. (2014) ^[@ref-172]^      MMP2               51                   \-               \-               60             70%           85%           \-

  Roy *et al*. (2014) ^[@ref-172]^      TIMP-1             51                   \-               \-               60             90%           70%           \-

  Jiao *et al*. (2014) ^[@ref-96]^      Nucleosides        \-                   202\             203              205            89.4%         97.1%         \-
                                                                                (gallbladder\                                                                
                                                                                cancer)                                                                      

  Metzger *et al*. (2013) ^[@ref-42]^   Urine Proteomic\   \-                   42               81               \-             83%           79%           0.87
                                        analysis                                                                                                             

  Biomarker combinations                                                                                                                                     

  Radon *et al*. (2015) ^[@ref-43]^     LYVE-1 +\          192                  \-               \-               87             \-            \-            0.89
                                        REG1A + TFF1                                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

4. Symptoms and cancer decision support tools
---------------------------------------------

Recently, pre-diagnostic symptom profiles have been investigated as an alternative way of detecting hepato-pancreato-biliary (HPB) cancers at an early stage ^[@ref-8],\ [@ref-9],\ [@ref-16],\ [@ref-44]^. It is now recognised that the onset of PDAC and BTC is heralded by a collection of gastrointestinal and constitutional symptoms ^[@ref-45]^. Although overlap occurs with other benign and malignant conditions, certain symptoms such as back pain, lethargy and new-onset diabetes have been identified as particularly suggestive of PDAC. Commonly performed blood tests such as liver function tests, glucose and haemoglobin also typically become abnormal in the months preceding diagnosis ^[@ref-46]^. Therefore, cancer decision support tools have been produced from combinations of symptoms and risk factors. In the UK, they have been introduced into general practices in 15 cancer networks to date ^[@ref-8]^, and their utility is currently being audited ^[@ref-47]^. Modification to existing tools to enhance their diagnostic accuracy can be expected in the future.

Endoscopy
=========

1. Endoscopic ultrasonography
-----------------------------

If there is a mass lesion on cross-sectional imaging, endoscopic ultrasonography with fine-needle aspiration (EUS-FNA) provides an alternative method for visualising and sampling the extra-hepatic biliary tree, pancreas, gallbladder or peri-hilar lymph nodes. EUS-FNA has a diagnostic accuracy for PDAC of between 65% and 96% ^[@ref-48],\ [@ref-49]^. In BTC, a single-centre study reported a sensitivity of 73%, which was significantly better in distal compared with proximal tumours (81% versus 59% respectively, *P*=0.04) ^[@ref-50]^. Recently, developed fine core biopsy needles appear to have improved diagnostic accuracy over traditional FNA needles, but randomised trials are awaited ^[@ref-49],\ [@ref-51],\ [@ref-52]^. Rapid onsite examination by a cytopathologist is used in some centres, particularly in North America, and has been shown to improve the yield of EUS-FNA in individual centres ^[@ref-53],\ [@ref-54]^ but this trend has not been borne out in recent randomised controlled trials ^[@ref-55]^.

To improve the diagnostic accuracy of EUS, it can also be combined with novel adjuncts such as contrast agents (SonoVue ^®^), transient elastography (TE) or confocal laser endomicroscopy (CLE). TE allows the measurement of the tissue firmness, which tends to be increased in malignant tissue. In a recent single-centre study from the UK, quantitative strain measurements were found to have high sensitivity but low specificity for the detection of PDAC ^[@ref-56]^. The technology to perform the techniques is available on most modern EUS machines and adds little time to the overall procedure time. The technique can be performed equally well by endosonographers with limited experience ^[@ref-57],\ [@ref-58]^ and is particularly advantageous in cases where the diagnosis remains uncertain after standard EUS has been performed ^[@ref-59]^. Contrast-enhanced EUS is performed with agents such as SonoVue ^®^ and allows visualisation of the early arterial phase and late parenchymal phase enhancement of the pancreas. Pancreatic tumours are generally hypovascular compared with the surrounding parenchyma ^[@ref-60],\ [@ref-61]^. Dynamic contrast EUS is a relatively novel method that allows the non-invasive quantification of the tumour perfusion compared with the pancreatic parenchyma by using software that is now built into a number of EUS scanners. The use of this technology is evolving but is expected to be most applicable when predicting tumour response to chemotherapeutic agents, particularly new drugs against vascular angioneogenesis ^[@ref-62],\ [@ref-63]^.

Recently, a needle-based confocal endomicroscope has also been developed which can be passed through a 19G FNA needle to assess indeterminate masses, cysts or lymph nodes. Malignancy in the hepatobilary tract is identified by the presence of irregular vessels, vascular leakage and large dark clumps ( [Figure 1](#f1){ref-type="fig"}) ^[@ref-64]^. In a recent study of 25 patients with indeterminate pancreatic masses referred for EUS-FNA, needle-based CLE was shown to be a safe and feasible technique ^[@ref-65]^.

![Novel diagnostic adjuncts to ERCP and EUS.\
( **a**) Cholangioscopic view of a malignant hilar stricture with visualisation of the ulcerated, friable biliary mucosa via the Spyglass cholangioscope system (Boston Scientific Corp, Massachusetts, USA). ( **b**) Confocal endomicroscopic image of pancreatic cancer, showing characteristic black clumps. Image was obtained using the Cellvizio AQ-Flex® probe which was introduced to the tumour via 19G FNA needle at the time of EUS.](f1000research-6-12275-g0000){#f1}

2. Endoscopic retrograde cholangiopancreatography
-------------------------------------------------

ERCP is typically undertaken when imaging demonstrates an indeterminate biliary stricture and tissue acquisition is required for cytological or histological assessment. Biliary brush cytology and endobiliary biopsy have a sensitivity for malignancy of 9--57% ^[@ref-29],\ [@ref-30],\ [@ref-66],\ [@ref-67]^. Most HPB tumours exhibit chromosomal aneuploidy ^[@ref-68]^; therefore, in some centres, fluorescence *in situ* hybridisation and digital image analysis are used to assess for the presence of DNA abnormalities in brush cytology ^[@ref-30],\ [@ref-69]^. Although these techniques have been adopted by only a few centres, the presence of polysomy is highly suggestive of BTC ^[@ref-30],\ [@ref-69]^.

Poor diagnostic accuracy in biliary brush and endobiliary samples has been attributed to their being non-targeted samples obtained with only fluoroscopic guidance ^[@ref-70]^. The single-operator cholangioscopy system (SpyGlass, Boston Scientific Corporation, Natick, MA, USA) introduced in 2006 and now superseded by the SpyGlass DS system enables intrabiliary biopsies under direct vision via small disposable forceps ( [Figure 1](#f1){ref-type="fig"}). In a recent systematic review, the sensitivity and specificity of cholangioscopy-guided biopsies in the diagnosis of malignant biliary strictures were 60.1% and 98.0%, respectively ^[@ref-71]^. Higher sensitivities are observed for intrinsic biliary malignancy compared with extrinsic compressing tumours ^[@ref-72]^. Several techniques have been employed to augment the visualised mucosa during cholangioscopy, including chromendoscopy with methylene blue ^[@ref-73]--\ [@ref-75]^, narrow-band imaging ^[@ref-76],\ [@ref-77]^ and autofluorescence ^[@ref-78]^.

During ERCP, a "CholangioFlex" confocal probe (Mauna Kea Technologies, Paris, France) can be placed down the working channel of a cholangioscope or duodenoscope to obtain real-time CLE images, which are akin to standard histology ( [Figure 1](#f1){ref-type="fig"}). If the images obtained from a point on the biliary mucosa contain dark areas, this is highly suggestive of malignancy ^[@ref-79],\ [@ref-80]^. The diagnostic accuracy of probe-based CLE was recently validated in a prospective multi-centre international study with 112 patients (71 with malignant lesions). Tissue sampling alone had a sensitivity, specificity and diagnostic accuracy of 56%, 100% and 72%, respectively. In comparison, ERCP with probe-based CLE had a sensitivity, specificity and diagnostic accuracy of 89%, 71% and 82%, respectively. Diagnostic accuracy increased to 88% when probe-based CLE and tissue sampling results were combined ^[@ref-81]^. CLE is also feasible in the pancreatic duct during pancreaticoscopy but, owing to concerns over pancreatitis, is rarely used. In a case report by Meining *et al*., the presence of a main duct-intraductal papillary mucinous neoplasia was confirmed by clear views of typical finger-like projections ^[@ref-82]^. Intraductal ultrasound in small studies has also been shown to have a diagnostic accuracy of up to 90% ^[@ref-83]^.

Conclusions
===========

Currently, the most widely used tumour marker in pancreaticobiliary malignancy is CA19-9. However, its use is limited by its elevation in a number of other benign and malignant conditions. Furthermore, it is not produced in approximately 7% of the population who are Lewis antigen--negative and is often undetectable when tumours are small. Over the last few years, a number of very promising biomarker panels have been identified which can detect tumours at an early stage when curative intervention could be possible. These markers are subject to ongoing validation studies but appear likely to be implemented into screening programmes, particularly for high-risk groups, in the near future. Novel endoscopic techniques such as per-oral cholangioscopy and confocal endomicroscopy can enhance the diagnostic accuracy of standard techniques and are increasingly available in large-volume centres worldwide.
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